plcxd3 Antibody

What is PLCXD3 and why is it significant in research?

PLCXD3 (Phosphatidylinositol-Specific Phospholipase C, X Domain Containing 3) is a protein that contains a PI-PLC X-box domain, which is conserved in many PLC isozymes from prokaryotes to mammals. The X-box domain is essential for the catalytic activity of PLC proteins . PLCXD3 has gained research significance due to its involvement in multiple cellular processes including:

• Insulin secretion in pancreatic islet cells

• Oncogenic signaling pathways when fused with other genes (e.g., PLCXD3-ALK fusion)

• Apoptosis regulation and cell proliferation, particularly in cancer cells

• Potential role in epithelial-mesenchymal transition

Research interest has increased after studies showed PLCXD3 expression is reduced in diabetic islets and its involvement in novel cancer-associated gene rearrangements .

What types of PLCXD3 antibodies are available for research applications?

Based on current research resources, several types of PLCXD3 antibodies are available for different experimental applications:

Most commercially available antibodies have been validated for Western Blot (WB) applications, while some have additional validations for immunohistochemistry (IHC) and immunofluorescence (IF) .

How should researchers optimize PLCXD3 antibody usage for Western blot applications?

For optimal Western blot results when using PLCXD3 antibodies, consider the following methodological approach:

• Sample preparation: Use RIPA buffer containing proteinase inhibitor cocktail and phosphatase inhibitors as demonstrated in functional studies of PLCXD3-ALK .

• Protein quantification: Implement the Pierce BCA Protein Assay Kit for accurate quantification of protein concentrations.

• Gel electrophoresis parameters:

  • Use 10-12% SDS-PAGE gels for optimal separation

  • Transfer onto PVDF membranes

• Antibody dilutions:

  • Primary antibody (PLCXD3): 1:1000 dilution, incubate overnight at 4°C

  • Secondary antibody: 1:5000 dilution, incubate for 60 minutes at room temperature

• Detection method: Use Western Lightning Plus-ECL system for specific protein detection .

• Controls: Include positive controls from tissues with known PLCXD3 expression (e.g., pancreatic islets), and negative controls using PLCXD3 knockdown samples .

For phosphorylation studies involving PLCXD3, ensure the addition of fresh phosphatase inhibitors immediately before cell lysis to preserve phosphorylation status .

What are the key considerations for immunofluorescence experiments using PLCXD3 antibodies?

When designing immunofluorescence experiments with PLCXD3 antibodies, researchers should follow these methodological guidelines:

• Fixation protocol: For cell culture slides, use paraformaldehyde (4%) for 15 minutes followed by permeabilization with 0.2% Triton X-100.

• Antibody concentration: Use anti-PLCXD3 rabbit polyclonal antibody at a concentration of 0.25-2 μg/mL as recommended for immunofluorescence applications .

• Incubation conditions:

  • Block endogenous peroxidase activity

  • Apply primary antibody overnight at 4°C

  • Incubate with secondary antibody for 30 minutes at room temperature

• Visualization strategy: PLCXD3 typically displays cytoplasmic staining pattern. Use appropriate nuclear counterstaining (e.g., DAPI) to establish cellular localization .

• Verification approaches: Include known positive control cells (e.g., NIH-3T3 cells transfected with PLCXD3) and negative controls (empty vector transfected cells) to validate staining specificity .

Research using PLCXD3-ALK fusion proteins has successfully employed this approach to validate expression in stably transfected cell lines .

How can researchers effectively analyze PLCXD3 involvement in signaling pathways?

To analyze PLCXD3's role in cellular signaling pathways, implement this comprehensive methodology:

• Pathway identification: Begin with bioinformatic analyses using KEGG enrichment to identify potential signaling pathways associated with PLCXD3. Published research indicates PLCXD3 involvement in JAK2/STAT3 signaling .

• Expression manipulation strategies:

  • Knockdown approach: Use small interfering RNA (specifically longer sequences like si2-PLCXD3) for effective silencing

  • Overexpression approach: Implement lentiviral transduction systems with pLVX-IRES-Puro vectors containing PLCXD3

• Downstream pathway verification:

  • Analyze phosphorylation status of pathway components (p-JAK2, p-STAT3, p-AKT, p-ERK)

  • Validate with specific antibodies against phosphorylated forms

  • Include parallel analysis of total protein levels

• Functional validation assays:

  • Cell proliferation: CCK8 assay or plate clone formation assay

  • Migration: Wound healing assay measured at 24h and 48h intervals

  • Invasion: Matrigel invasion assay with appropriate controls

  • Apoptosis markers: BAX, P53, and BCL2 by Western blot analysis

• Data integration: Correlate PLCXD3 expression levels with pathway activation status and functional outcomes using multivariate analysis to establish causal relationships.

Research has shown that PLCXD3 can activate downstream signaling including STAT3, AKT, and ERK pathways, making these excellent targets for verification .

What methodologies are recommended for investigating PLCXD3 gene rearrangements in cancer research?

For thorough investigation of PLCXD3 gene rearrangements in cancer research, implement this methodological framework:

• Initial screening approaches:

  • Next-generation sequencing (NGS) to identify novel fusion genes involving PLCXD3

  • RNA sequencing to confirm transcriptional expression of fusion genes

  • Differential expression analysis between tumor and normal tissues

• Validation techniques:

  • Immunohistochemistry using Ventana IHC-ALK (D5F3) assay for detection of ALK rearrangements

  • Fluorescence in situ hybridization (FISH) to confirm gene rearrangements

  • RT-PCR followed by Sanger sequencing to verify fusion breakpoints

• Functional characterization:

  • Construct expression plasmids containing the fusion gene (e.g., PLCXD3-ALK)

  • Establish stable cell lines using lentiviral transduction systems

  • Perform soft agar colony formation assays to assess anchorage-independent growth

  • Analyze downstream pathway activation via Western blotting

• Therapeutic response assessment:

  • Evaluate sensitivity to relevant inhibitors (e.g., ALK inhibitors for PLCXD3-ALK)

  • Measure cell viability using CCK8 assay following treatment

  • Monitor tumor growth in xenograft models with and without targeted therapy

A comprehensive example of this approach was successfully employed in the identification and characterization of the novel PLCXD3-ALK fusion in lung squamous cell carcinoma, where the fusion was confirmed to be oncogenic and responsive to ALK inhibitors .

How can researchers address specificity issues when using PLCXD3 antibodies?

When encountering specificity concerns with PLCXD3 antibodies, implement these methodological approaches to ensure reliable results:

• Antibody validation strategy:

  • Perform Western blot analysis using both positive controls (tissues/cells with confirmed PLCXD3 expression) and negative controls (PLCXD3 knockdown samples)

  • Compare staining patterns across multiple antibodies targeting different epitopes of PLCXD3

  • Validate results with orthogonal methods (e.g., mRNA expression analysis)

• Cross-reactivity assessment:

  • Check for potential cross-reactivity with other PLC family members (PLCXD1, PLCXD2)

  • Refer to the list of synonyms and alternative names (B130016O10Rik, wu:cegs2770, wu:fc10h08, wu:fq34d10, zgc:110845) to identify potential sources of non-specific binding

• Optimization parameters:

  • Test multiple antibody dilutions (1:20-1:50 for IHC, 0.25-2 μg/mL for IF)

  • Adjust blocking conditions to reduce background signal

  • Implement antigen retrieval methods appropriate for the tissue type

• Complementary verification approaches:

  • Use RNA interference to confirm specificity of observed signals

  • Employ epitope-tagged PLCXD3 constructs as additional controls

  • Consider mass spectrometry-based verification for critical applications

Studies investigating novel PLCXD3 functions have demonstrated that careful antibody validation is crucial, particularly when examining complex biological systems or newly discovered fusion proteins .

What are the optimal conditions for investigating PLCXD3 expression changes in disease models?

To effectively investigate PLCXD3 expression changes in disease models, researchers should follow these methodological guidelines:

• Experimental design considerations:

  • Include appropriate time-course analyses to capture temporal changes

  • Match control and experimental samples for relevant variables (age, sex, genetic background)

  • Use statistically determined sample sizes based on anticipated effect size

• Sample processing protocol:

  • For tissue samples: Use consistent collection and preservation methods

  • For cell models: Standardize culture conditions, particularly glucose concentrations which can affect PLCXD3 expression

  • Extract protein/RNA using methods that preserve posttranslational modifications

• Expression analysis techniques:

  • Quantitative RT-PCR: Normalize to multiple reference genes stable in the tissue/condition

  • Western blot: Implement densitometric analysis using standardized loading controls

  • Immunohistochemistry: Use digital image analysis for quantification

• Disease-specific considerations:

  • Diabetes models: Control for glucose levels (11.1 mM control, 16.7 and 22.2 mM for hyperglycemia models)

  • Cancer models: Compare matched tumor-normal pairs from the same patient when possible

  • Consider correlation with clinical parameters (BMI, HbA1c, tumor stage)

Research has shown that PLCXD3 expression is reduced in diabetic islets and correlates negatively with BMI and HbA1c. In contrast, PLCXD3 shows elevated expression in certain cancers, demonstrating the importance of context-specific analysis .

What methodological approaches should be used to investigate the role of PLCXD3 in epithelial-mesenchymal transition?

To thoroughly investigate PLCXD3's role in epithelial-mesenchymal transition (EMT), implement this comprehensive methodological framework:

• Expression manipulation approach:

  • Establish stable knockdown and overexpression models in relevant cell lines

  • Use inducible expression systems to study temporal effects on EMT progression

  • Consider CRISPR-Cas9 genome editing for complete knockout studies

• EMT marker analysis panel:

  • Epithelial markers: E-cadherin (protein and mRNA levels)

  • Mesenchymal markers: N-cadherin, MMP2, MMP9

  • EMT transcription factors: Snail, Slug, ZEB1/2, Twist

  • Analyze using multi-parameter approaches combining Western blotting, qPCR, and immunofluorescence

• Functional assessment methods:

  • Migration: Wound healing assay with time-lapse microscopy

  • Invasion: Matrigel invasion assays with quantitative analysis

  • Morphological changes: Phase-contrast microscopy and cytoskeletal staining

  • Adhesion properties: Cell-substrate adhesion assays

• Mechanistic investigation:

  • Pathway inhibition studies using specific JAK2/STAT3 inhibitors

  • Co-immunoprecipitation to identify PLCXD3 interaction partners

  • Chromatin immunoprecipitation to assess transcriptional regulation of EMT genes

Research has demonstrated that PLCXD3 knockdown lowers levels of MMP2, MMP9, and N-cadherin while increasing E-cadherin, whereas PLCXD3 overexpression produces opposite effects, strongly indicating its role in EMT regulation .

How can researchers design experiments to investigate the therapeutic potential of targeting PLCXD3 or its fusion proteins?

To design robust experiments investigating therapeutic potential of targeting PLCXD3 or its fusion proteins, implement this methodological framework:

• Target validation strategy:

  • Confirm target expression in disease models using validated antibodies

  • Establish correlation between expression levels and disease progression/prognosis

  • Validate functional significance through knockdown/overexpression studies

• Therapeutic approach selection:

  • For PLCXD3-ALK fusion: Test ALK inhibitors (crizotinib, alectinib) in various concentrations

  • For native PLCXD3: Consider siRNA-based approaches or small molecule inhibitors

  • For pathway intervention: Target downstream effectors like JAK2/STAT3

• In vitro evaluation methods:

  • Cell viability assays (CCK8) with dose-response curves

  • Apoptosis assessment (flow cytometry, Western blot for BAX, P53, BCL2)

  • Signaling pathway analysis (phosphorylation status of downstream targets)

  • Functional assays relevant to disease phenotype (migration, invasion, colony formation)

• In vivo model development:

  • Generate xenograft models using cells expressing target proteins

  • Design treatment protocols with appropriate controls

  • Monitor tumor growth, survival, and toxicity parameters

  • Perform ex vivo analysis of harvested tumors for molecular and pathological changes

• Translational considerations:

  • Correlate experimental findings with patient data

  • Design potential biomarkers for patient stratification

  • Develop combinatorial approaches with existing therapies

Research on PLCXD3-ALK has demonstrated successful implementation of this framework, confirming therapeutic efficacy of ALK inhibitors against this novel fusion protein in both in vitro and in vivo models, with validation in a clinical case .

How can researchers effectively design antibody-based approaches for detecting novel PLCXD3 fusion proteins in clinical samples?

For effective detection of novel PLCXD3 fusion proteins in clinical samples, implement this comprehensive methodological framework:

• Epitope selection strategy:

  • Design antibodies targeting the retained portions of PLCXD3 in fusion proteins

  • Consider junction-specific antibodies for unique fusion breakpoints

  • Evaluate epitope conservation across potential fusion variants

• Multi-modal detection approach:

  • Immunohistochemistry: Optimize antigen retrieval methods and antibody dilutions (1:20-1:50)

  • Immunofluorescence: Use dual-color staining to detect both fusion partners

  • Proximity ligation assay: For detecting protein-protein interactions in intact tissue

• Validation protocol:

  • Test antibodies on cell line models expressing known PLCXD3 fusions

  • Implement orthogonal detection methods (RT-PCR, FISH) for confirmation

  • Include appropriate controls (wild-type PLCXD3, known fusion-positive samples)

• Clinical implementation considerations:

  • Develop standardized protocols suitable for FFPE tissues

  • Establish scoring systems for quantitative assessment

  • Compare with gold standard methods like next-generation sequencing

  • Determine sensitivity and specificity in clinical validation cohorts

• Data analysis framework:

  • Correlate detection results with clinical outcomes

  • Analyze patterns of co-occurring molecular alterations

  • Implement machine learning approaches for automated detection

Research on PLCXD3-ALK has demonstrated successful application of IHC using ALK (D5F3) antibody combined with FISH confirmation. Similar approaches could be adapted for detection of other PLCXD3 fusion proteins in clinical settings .